Showing 2611-2620 of 10469 results for "".
DermWireTV: Inclusion in Derm; Amgen, Incyte, Janssen, Dermavant Updates; Klisyri Launch; More
https://practicaldermatology.com/topics/practice-management/dermwiretv-inclusion-in-derm-amgen-incyte-janssen-dermavant-updates-klisyri-launch-more/19901/For an article in Pediatric Dermatology, Linda Oyesiku, MPH, a student member of the Society for Pediatric Dermatology, describes historical obstacles to inclusion and highlights opportunities to expand representation and reduce bias in dermatology. Research conducted by The Martec Group using theirBuilding an Inflammatory Clinic
https://practicaldermatology.com/series/pa-perspectives/building-inflammatory-clinic/26436/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses how to build an inflammatory clinic as an advanced practice practitioner (APP). Andrew also discusses what factors APPs should consider when prescribing mediFirst, Do No Harm
https://practicaldermatology.com/conferences/scale-2023/first-do-no-harm/20206/Joel L. Cohen, MD, and Mathew M. Avram, MD, JD, discuss why dermatologists should report any side effects to the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database.Tolerability of JAK Inhibitors Used in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/tolerability-of-jak-inhibitors-used-in-dermatology/20126/Although safety and tolerability are often intertwined, they are distinct considerations. Topical and oral JAKs used in dermatology today seem to offer good tolerability. Adelaide A. Hebert, MD and Matthew Zirwas, MD discuss potential side effects, management, and monitoring in pediatric and adult pDermWireTV: Doximity Physician Compensation Report, EADV Updates, PsO in the Know
https://practicaldermatology.com/topics/psoriasis/dermwiretv-doximity-physician-compensation-report-eadv-updates-pso-in-the-know/19870/Doximity’s fourth annual Physician Compensation Report shows a widening of the gender pay gap. From biologics and investigational molecules for psoriasis to socks to prevent foot odors, the European Academy of Dermatology and Venereology annual meeting highlights emerging therapies for dermatology pCrisis Management: Office Operations, Part 1
https://practicaldermatology.com/topics/practice-management/crisis-management-office-operations-part-1/18181/How are primarily cosmetic dermatology practices dealing with shutdowns and preparing for the future? Host Neal Bhatia, MD discusses with Deirdre Hooper, MD, Ashish Bhatia, MD, Kevin Pinski, MD, and Nancy Samolitis, MD.Humira Approved for HS, NewDerm LIVE Hits Hollywood
https://practicaldermatology.com/topics/psoriasis/dermwiretv-humira-approved-for-hs-newderm-live-hits-hollywood/18831/AbbVie's Humira has become the first and only FDA-approved therapy for adults with moderate to severe hidradenitis suppurativa. NewDermLIVE, a new meeting for dermatologists new to practice—and those not so new to practice—has brought a new kind of meeting into the dermatology space. Solta MedicaImplications of the Overlap Between CSU and Atopic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/implications-of-the-overlap-between-csu-and-atopic-dermatitis/50850/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, is joined by Northwestern University Feinberg School of Medicine Associate Professor Walter Liszewski, MD, to discuss the article “Co-existence of chronic spontaneous urticaria and atopic dermatitis: clinical and immunological perspecClinical Conversations: A conversation with Dr Angela Lamb, a dermatologist and professor in New York, New York
https://reachmd.com/programs/nemluvio-peer-network/clinical-conversations-a-conversation-with-dr-angela-lamb-a-dermatologist-and-professor-in-new-york-new-york/37237/Dr Angela Lamb discusses her approach to treating prurigo nodularis (PN) and atopic dermatitis (AD). She’ll explain how NEMLUVIO®, the first and only neuroimmune-targeted therapy that blocks IL-31RA, targets both immune and neuronal pathways and addresses chronic itch, inflammation, and barrier disrPractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 6
https://practicaldermatology.com/series/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-6/32904/In the final installment of a six-part series, host Neal Bhatia, MD, FAAD, and guests Laura K. Ferris, MD, PhD, FAAD, and Jason E. Hawkes, MD, MS, FAAD, recap the recommended protocol for treating generalized psoriasis treatment, starting from the initial diagnosis, as well as the safety of targeted